|
Status |
Public on Jan 20, 2015 |
Title |
GSK126.2 |
Sample type |
RNA |
|
|
Source name |
OVISE cell line, GSK126 treated
|
Organism |
Homo sapiens |
Characteristics |
cell line: ARID1A mutated clear cell ovarian cancer OVISE condition: EZH2 inhibited batch: batch 2
|
Treatment protocol |
Matrigel media was treated with either vehicle control DMSO, 1 ug/mL doxycycline to induce wild type ARID1A expression or 5μM GSK126 to inhibit EZH2
|
Growth protocol |
ARID1A mutated clear cell ovarian cancer OVISE cells restored for wild type ARID1A expression or treated with 5μM GSK126 were cultured in 3D using Matrigel.
|
Extracted molecule |
total RNA |
Extraction protocol |
Extraction using trizol, Rneasy clean-up and Dnase I treated
|
Label |
biotin
|
Label protocol |
Biotin Labeling of RNA at 400ng with Ambion Illumina® TotalPrep RNA Amplification Kit
|
|
|
Hybridization protocol |
Hybridized on Illumina Human-HT12 v4 Expression BeadChip Kit using Illumina whole-Genome Gene Exprssion with Intellihyb Seal system which detect signal with streptavidin-Cy3
|
Scan protocol |
Illumina Setting with PMTFactor=2
|
Description |
inhibition of EZH2 by GSK126 SAMPLE 8
|
Data processing |
Illumina GenomeStudio software was used to export expression levels and detection p-values for each probe of each sample. Signal intensity data was quantile normalized and genes that showed insignificant detection p-value (p>0.05) in all samples were removed from further analysis.
|
|
|
Submission date |
Feb 13, 2014 |
Last update date |
Jan 20, 2015 |
Contact name |
Louise C Showe |
E-mail(s) |
[email protected]
|
Phone |
215-898-3791
|
Organization name |
The Wistar Institute
|
Lab |
Dr. Louise Showe
|
Street address |
3601 Spruce St
|
City |
Philadelphia |
State/province |
PA |
ZIP/Postal code |
19104 |
Country |
USA |
|
|
Platform ID |
GPL10558 |
Series (1) |
GSE54979 |
Targeting EZH2 methyltransferase activity in ARID1A mutated cells as a synthetic lethal therapeutic strategy |
|